INB-400 is under clinical development by IN8bio and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Recurrent Glioblastoma Multiforme (GBM) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how INB-400’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

INB-400 overview

INB-400 is under development for the treatment of newly diagnosed recurrent glioblastoma multiforme and solid tumor such as ovarian cancer. The therapeutic candidate is developed based on DeltEx platform and drug resistant immunotherapy (DRI) platform technology and consists of genetically modified gamma delta T cells administered along with chemotherapy. The drug candidate acts by targeting PARP for solid tumors. 

IN8bio overview

IN8bio is a clinical-stage biopharmaceutical company that focused on discovery, and development of gamma-delta T cell product candidates for solid and liquid tumors. The company is headquartered in New York City, New York, the US.

For a complete picture of INB-400’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.